公开(公告)号：US20190300520A1

公开(公告)日：2019-10-03

申请号：US16317218

申请日：2017-07-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qinghong Fu ,  Xiaojun Zhang ,  Eldon Scott Priestley ,  Oz Scott Halpern ,  Samuel Kaye Reznik ,  Jeremy M. Richter

IPC: C07D417/14 ,  C07D513/04 ,  C07D417/10

Abstract: Disclosed are compounds of Formula (I) to (IV): [INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

公开(公告)号：US20190248771A1

公开(公告)日：2019-08-15

申请号：US16317232

申请日：2017-07-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jeremy M. Richter ,  Xiaojun Zhang ,  Eldon Scott Priestley

IPC: C07D413/10 ,  A61P7/02 ,  C07D403/10 ,  C07D417/10 ,  C07D417/14

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a monocyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.